Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig.6.B,C
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF40 (in situ)
|
|
|
|
Fig. 6. CD
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 CRISPR
NF33-39 (in situ)
|
|
|
|
Fig.S15.A-H
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 CRISPR
NF44 (immunohistochemistry)
|
|
|
|
Fig. 3. B
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 CRISPR
NF44 (microscopy)
|
|
|
|
Fig.6.F,G
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF39 (in situ)
|
|
|
|
Fig.6.L,M
Smith SJ et al. (2020)
|
Xla Wt + adprhl1 MO
NF39 (in situ)
|
|
|